All News

RheumNow Podcast square

Goofy But True

d Jack Cush, MD

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.

Read Article
BP

Hypertension Associated with RA and OA

d Jack Cush, MD

While hypertension and arthritis are very common disorders, the association between them is unclear.  Analysis of NHANES data suggests that both rheumatoid arthritis (RA) and osteoarthritis (OA) are strongly associated with hypertension (HTN).

Read Article
genes_0.jpg

Genetic Testing for Autoinflammatory Disease

d Jack Cush, MD

Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.

Read Article
NICE Guidelines on Gout Diagnosis and Management NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness. https://t.co/a8iyCe3szJ https://t.co/6Jy7dOT4yX

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout: diagnosis and management—summary of NICE guidance https://t.co/tVHkSMusk6 https://t.co/A7U1DlI7tO

Links:

Dr. John Cush RheumNow ( View Tweet)
SURPRISED? Psoriasis pts have a known increased risk of CV disease. But did you know several papers & metanalyses show increased risk of abdominal aortic aneurysm in PSO (HR 1.30), worse w/ dz activity; lost w/ age, female, DM? https://t.co/9ihyubUgCI https://t.co/W1JiXV0yOX https://t.co/Nq6aVBjPuK

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/j00yWpBbq3 https://t.co/7BK2mopssc

Links:

Dr. John Cush RheumNow ( View Tweet)
USPSTF recommends clinicians prescribe Statins for the primary CVD prevention in adults (40-75 yrs) w/ 1 or more CVD risk factors (ie, dyslipidemia, DM, HTN, smoking) & 10-year CVD risk of 10% or greater. Inflammatory dz is considered a CV risk enhancer https://t.co/1Opblbiz7B https://t.co/xSw2uPUoKK

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of steroids & immunosuppressants on cancer outcomes in checkpoint inhibitor therapy - Steroid use "for irAEs may not have a large deleterious effect on overall survival" - DMARDs for irAE "a major drawback in the delay in the onset of response" https://t.co/8o8JBMpqML https://t.co/bWuLT3zYPm

Links:

Dr. John Cush RheumNow ( View Tweet)
MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/BZwY7DpmIb https://t.co/gNhhuhmTG5

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow. https://t.co/ZaWnjxiR3W https://t.co/8CElIxWk1v https://t.co/ZVayc3Qt1r

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR/ACR Classification in MDA5+ Myositis Patients A current analysis suggests that nearly 30% of MDA5 IIM patients may be missed by the 2017 EULAR/ACR classification criteria for IIM. https://t.co/rS25rL5fGO https://t.co/Yw7sGmPW5G

Links:

Dr. John Cush RheumNow ( View Tweet)
Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/szQmNPO0eu https://t.co/z4tdP4I1kc

Links:

Dr. John Cush RheumNow ( View Tweet)
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO Sponsored by Lilly USA Listen to Philip Mease and April Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and skin concerns. https://t.co/lTfz2kUr51 https://t.co/jVp8Uk0uH5

Links:

Dr. John Cush RheumNow ( View Tweet)
Longitudinal study of 411 adult fibromyalgia pts showed that 73.2% had depression at enrollment. Higher depression scores at baseline predicted poorer functional outcomes. Effectively treated depression resulted in improved functioning at follow-up. https://t.co/D43r4Z5llU https://t.co/a9EgyJLHza

Links:

Dr. John Cush RheumNow ( View Tweet)
Head Scratcher? Study of UK Biobank cohort (n=380,380) shows those taking Rx Folate had increased risk of COVID-19 Dx (OR 1.51; 1.42–1.61) and Death (OR 2.64; 2.15–3.24). MTX use (+/- folate) had no increase in COVID or COVID death(1.07;0.57–1.98) https://t.co/MLE1sL7KG2 https://t.co/adoLO9qLON

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. https://t.co/VzQBFgvAqu https://t.co/r0pQuoDVcn

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 497 pts referred by general practitioners to rheumatologist (2018-19) showed: - GP Dx changed by Rheum in 58% - Low complexity Dx (FM, OA) acct for 50% referrals - 46% of referrals inappropriate - GP correlations w/ Rheum Dx poor (κ < 0.5) https://t.co/q592iHQZbq https://t.co/XyPdtpHQGK

Links:

Dr. John Cush RheumNow ( View Tweet)

Recent review of AOSD suggests: - AOSD & SJIA are the same - Classify dz as systemic or articular - #MAS occurs in up to 23% - Yamaguchi & Fautrel criteria are widely used - Cytokines important: IL-1, IL-6, IL-18, IL-37 - only Canakinumab is FDA-approved https://t.co/4ERA56Wqcb https://t.co/FkIWxIrwxX

Links:

Dr. John Cush RheumNow ( View Tweet)
NICE Guidelines on Gout Diagnosis and Management NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness. https://t.co/ckDrfVAynN https://t.co/jzBviwpxGL

Links:

Dr. John Cush RheumNow ( View Tweet)
×